Drugs / DC cell Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06036355 | Sep 2023 → Apr 2024 | — | Shanghai Cell Therapy Group Co.,Ltd | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT06477614 | Jun 2024 → Dec 2030 expected | cancer | Second Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DC cell vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06036355 ↗ |
| Modality | Cell therapy | “DC vaccine is a kind of immune cells expanded in vitro” NCT06036355 ↗ |
| Route | Other | “The manufactured DC cells are subcutaneously or intra-tumor injected into the patient.” NCT06477614 ↗ |
| Route | Subcutaneous | “The manufactured DC cells are subcutaneously or intra-tumor injected into the patient.” NCT06477614 ↗ |